# Supplementary Materials: Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma

Lydia Visser, Rui Wu, Bea Rutgers, Arjan Diepstra and Anke van den Berg

## Table S1. Leukocyte subpopulations and antibodies used.

<table>
<thead>
<tr>
<th>Leukocyte Subpopulation</th>
<th>Immunophenotype</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-cells</td>
<td>CD20+</td>
<td>BD</td>
</tr>
<tr>
<td>T-cells</td>
<td>CD3+</td>
<td>Dako</td>
</tr>
<tr>
<td>Th cells</td>
<td>CD4+</td>
<td>BD</td>
</tr>
<tr>
<td>Cytotoxic T-cells</td>
<td>CD8+</td>
<td>BD</td>
</tr>
<tr>
<td>NK cells</td>
<td>CD56+</td>
<td>IQ</td>
</tr>
<tr>
<td>Macrophages</td>
<td>CD68+</td>
<td>R&amp;D</td>
</tr>
<tr>
<td>Double positive T-cells</td>
<td>CD4+CD8+</td>
<td>BD/BD</td>
</tr>
</tbody>
</table>

### Naïve Th cells
- CCR7+CD45RA+ in CD4+ : R&D/Own lab/BD

### Central memory Th cells (TCM)
- CCR7+CD45RA− in CD4+ : R&D/Own lab/BD

### Effector memory Th cells (TEM)
- CCR7-CD45RA− in CD4+ : R&D/Own lab/BD

### Terminally differentiated Th cells (TEMRA)
- CCR7-CD45RA+ in CD4+ : R&D/Own lab/BD

### Activation of Th cells
- CD69+ in CD4+ : IQ/BD
- CD25 in CD4 : IQ/IQ

### Th1 cells
- ST2L+ in CD4+ : R&D/BD
- CXC4+ in CD4+ : R&D/IQ

### Th2 cells
- GITR+ in CD4+ : R&D/BD
- GITR+ CD25+ in CD4+ : R&D/IQ/BD
- CD127low CD25+ in CD4+ : BD/BD
- CD127low CD25 in CD4+ : BD/IQ/BD
- CD152+ in CD4+ : BD/IQ/BD
- CD152+ CD25+ in CD4+ : BD/IQ/BD
- FoxP3+ in CD4+ : BD/BD
- CD25+ FOXP3+ in CD4+ : IQ/IQ/BD/BD
- CD25+ CD45RA− in CD4+ : IQ/Own lab/BD

### Regulatory T-cells
- CD57+ in CD4 : BD/BD
- PD-1+ in CD4 : Bio/BD
- PD-1+ CD57+ in CD4 : Bio/BD/BD

### T follicular helper cells
- CXCR5+ ICOS+ in CD4+ : BD/R&D/BD
- Bcl6+ in CD4+ : R&D/BD
- CXCR5+ BCL6+ in CD4+ : R&D/BD
- Bcl6+ CD57+ in CD4+ : R&D/BD

### T follicular helper regulatory cells
- CXCR5+ICOS+ in CD4+CD25+ : R&D/BD/BD/IQ

### Cytotoxic Th cells
- TIA-1+ in CD4+ : IQ/BC
- Granzyme-B+ in CD4+ : IQ/BD

### Activation of cytotoxic T-cells
- CD25+ in CD8+ : IQ/BD
- CD69+ in CD8 : IQ/BD

### Cytotoxic T-cells
- CXCR4+ in CD8+ : R&D/BD
- CXCR3+ in CD8+ : R&D/BD
- TIA-1+ in CD8+ : BC/BD
- Granzyme B+ in CD8+ : BD/BD
<table>
<thead>
<tr>
<th>Leukocyte Subpopulation</th>
<th>Immunophenotype</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>NK cells</td>
<td>CD56+ in CD3−</td>
<td>IQ/BD</td>
</tr>
<tr>
<td></td>
<td>CD16+ in CD3−</td>
<td>R&amp;D/BD</td>
</tr>
<tr>
<td></td>
<td>CD57+ in CD3−</td>
<td>BD/BD</td>
</tr>
<tr>
<td></td>
<td>CD56+ CD16+ in CD3−</td>
<td>IQ/R&amp;D/BD</td>
</tr>
<tr>
<td></td>
<td>CD56+ CD107a+ in CD3−</td>
<td>IQ/BD/BD</td>
</tr>
<tr>
<td></td>
<td>CD56+CD16+ in CD3+</td>
<td>IQ/R&amp;D/BD</td>
</tr>
<tr>
<td>M2 Macrophages</td>
<td>CD163+in CD68+</td>
<td>R&amp;D/R&amp;D</td>
</tr>
</tbody>
</table>

BD: BD Biosciences; IQ: IQ Products, Groningen, The Netherlands; R&D: R&D systems, Minneapolis, MN, USA; Dako: Dako Products, Glostrup, Denmark; BC: Beckman Coulter, Woerden, The Netherlands.